| Metric | FY2023 | FY2022 |
|---|---|---|
| Research and development | $25.2M+65.0% | $15.3M |
| General and administrative | $13.5M+36.9% | $9.8M |
| Change in fair value of contingent consideration | $2.7M+481.2% | -$712K |
| Total operating expenses | $41.4M+69.6% | $24.4M |
| Operating loss | -$41.4M-69.6% | -$24.4M |
| Change in fair value of warrant liability | -$182K-706.7% | $30K |
| Interest income | $2.6M+759.3% | $300K |
| Total other income (expense), net | $2.4M+626.1% | $330K |
| Net loss | -$39.0M-62.0% | -$24.1M |
| Net loss per common share basic | -$2360.00+17.8% | -$2870.00 |
| Net loss per common share diluted | -$2360.00+17.8% | -$2870.00 |
| Weighted-average common shares outstanding used to calculate basic net loss per common share | $16492132000.00+96.4% | $8397088000.00 |
| Weighted-average common shares outstanding used to calculate diluted net loss per common share | $16492132000.00+96.4% | $8397088000.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.